Figure 3 Overall survival, according to treatment group

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outcome of Salvage Total Laryngectomy Following Organ.

Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Copyright © 2003 American Medical Association. All rights reserved.

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 1 Histopathology of low-grade glioma

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Schematic illustration of different clinical trial designs

Figure 3 Molecular subgroups of glioblastoma,

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Understanding EMPA-REG OUTCOME

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 The association between CD8+ T‑cell density of the tumour

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 4 Flow chart of the MDS MSA Study Group aims

Nat. Rev. Neurol. doi: /nrneurol

Understanding EMPA-REG OUTCOME

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Figure 3 Stroke-related deaths and DALYs by country development status

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Combining population-wide and high-risk strategies

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Figure 2 Logistical requirements for autologous

Nat. Rev. Neurol. doi: /nrneurol

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Plot with best overall response and study duration.

Nat. Rev. Neurol. doi: /nrneurol

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Figure 1 Timing of the effects of deep brain stimulation

Osteoarthritis year 2010 in review: non-pharmacologic therapy

Sharif B. Missiha, Mario Ostrowski, E. Jenny Heathcote

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Effects of chemotherapy and radiotherapy on spermatogenesis in humans

Highlighting Unmet Needs: Real Patients, Difficult Choices

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders Martin Benesch, MD, H. Joachim.

Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Presentation transcript:

Figure 3 Overall survival, according to treatment group Figure 3 | Overall survival, according to treatment group. Results from the Radiation Therapy Oncology Group (RTOG) 9802 trial7. All hazard ratios in the analyses of overall survival are for death, and all P values are two-sided. Tick marks indicate censored data. There were too few events among patients without the IDH1 Arg132His mutation to assess the association with treatment. PCV, procarbazine, lomustine and vincristine; RT, radiation therapy. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Buckner, J. et al. (2017) Management of diffuse low-grade gliomas in adults — use of molecular diagnostics Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.54